Nostra Esperienza Nel Trattamento Del Carcinoma Prostatico in Stadio Avanzato Con Lh-Rh Analoghi

Byar D. P. : The Veterans Administration Cooperative. Urological Research Group, studies of cancer of the prostate. Cancer, 32; 1126 (1973).

Eisenberger M. A. , O'Dwyer P. J. , Friedman M. A. : Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J. Clin. Oncol., 4; 414–424 (1985).

Kirk D. : Prostatic carcinoma. Brit. Med. J., 290; 875–876 (1985).

Koutsiliers M. , Fwon N. : Objective response and disease outcome in 59 patients with stage D₂ prostatic cancer treated with either buserelin or orchiectomy. Disease aggressivity and its associations with response and outcome. Urology, 27; 221–288 (1985).

Rajeifer J. , Handelsman D. M. : Comparison of the efficacy of subcutaneous and nasal spray Buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer. Fertil. & Steril., 46; 104–110 (1936).

Trachtenberg J. : Optimal testosterone concentration for the treatment of prostatic cancer. J. Urol., 133; 888–890 (1985).

Waxman J. H. , Wass J. A. : Treatment of advanced prostatic cancer with buserelin an analogue of gonadotroprin releasing hormone. Brit. J. Urol., 55; 737–742 (1983).